FLURESS | FLURESS [Akorn, Inc.] | BioPortfolio

12:02 EST 27th January 2019 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, USP(0.25%/0.4%)

Rx only Sterile

Fluress (Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, USP) is a sterile ophthalmic solution combining a disclosing agent with an anesthetic agent.

Fluorescein sodium is a disclosing agent with molecular formula CHNaO, molecular weight 376.28, and chemical structure:

Spiro[isobenzofuran-1 (3H), 9'-[9H]xanthene]-3-one. 3'6'-dihydroxy, Disodium salt

Benoxinate Hydrochloride is an anesthetic agent with molecular formula C17H28N2O3•HCl, molecular weight 344.88, and chemical structure:

Benzoic acid, 4-amino-3-butoxyl-,2-(diethylamino) ethyl ester, monohydrochloride

Each mL contains:

Actives: Benoxinate Hydrochloride 4 mg (0.4%). Fluorescein Sodium 2.5 mg (0.25%).

Preservative: Chlorobutanol 10 mg (1%).

Inactives: Boric Acid, Povidone, Sodium Hydroxide and/or Hydrochloric Acid may be added to adjust pH (4.3 to 5.3), and Purified Water USP.

Fluress is the combination of a disclosing agent with a rapidly acting anesthetic agent of short duration.

For procedures requiring a disclosing agent in combination with an anesthetic agent such as tonometry, gonioscopy, removal of corneal foreign bodies and other short corneal or conjunctival procedures.

Known hypersensitivity to any component of this product.


Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss.


Fluress (Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, USP) should be used cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism. The long-term toxicity is unknown; prolonged use may possibly delay wound healing. Although exceedingly rare with ophthalmic application of local anesthetics, systemic toxicity (manifested by central nervous system stimulation followed by depression) may occur.

Protection of the eye from irritating chemicals, foreign bodies and rubbing during the period of anesthesia is very important. Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water prior to use. Patients should be advised to avoid touching the eye until the anesthesia has worn off.

Pregnancy Category C. Animal reproduction studies have not been conducted with Fluress. It is also not known whether Fluress can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Fluress should be given to a pregnant woman only if clearly needed.

Caution should be exercised when Fluress is administered to a nursing woman.

The safety and effectiveness of this product in pediatric patients has not been established.

Occasional temporary stinging, burning and conjunctival redness have been reported after use of ocular anesthetics, as well as a rare severe, immediate-type, apparently hyperallergic corneal reaction with acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing or large areas of necrotic epithelium, corneal filaments and sometimes, iritis with descemetitis.

Allergic contact dermatitis with drying and fissuring of the fingertips has been reported.

Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating.

Deep ophthalmic anesthesia: 2 drops in each eye at 90 second intervals for 3 instillations.

NOTE: The use of an eye patch is recommended.

Fluress is supplied as 5 mL contained in a 10 mL plastic dropper bottle with a separate sterile dropper applicator. (NDC 17478-640-10)

Refrigerate at 2° to 8°C (36° to 46°F). User may store at room temperature for up to one month. Store in carton until empty to protect from light. Keep tightly closed.

U.S. PATENT NO. 3306820



Manufactured by: Akorn, Inc.Lake Forest, IL 60045

FS00N Rev 05/08

NDC 17478-640-10 Akorn Logo

5 mL


Fluorescein Sodium and

Benoxinate Hydrochloride

Ophthalmic Solution, USP

(0.25% / 0.4%)

Rx only Sterile

NDC 17478-640-10

With Sterile Dropper


Fluorescein Sodium

and Benoxinate


Ophthalmic Solution, USP

(0.25% / 0.4%)

Rx only

5 mL Sterile

Akorn Logo


Akorn, Inc.

Active Ingredients


Drugs and Medications [0 Results]


Clinical Trials [0 Results]


PubMed Articles [0 Results]


Quick Search

Relevant Topics

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Anesthesia is the loss of feeling or sensation in all or part of the body. It may result from damage to nerves or can be induced by an anesthetist (a medical professional) using anesthetics such as thiopental or propofol or sevoflurane during a surgical ...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record